Deals accompany new phase 1 trial starts
First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.
Revolution mortgages royalties for more cash
“We need all the capital we can get our hands on," the company states.
Better late than never for Datroway in lung cancer
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
ArriVent goes Further into PACC mutations
The group is aiming for accelerated approval with the upcoming Alpacca trial.
Nuvalent loses ground in the front line
Zidesamtinib is having a hard time catching up with Ibtrozi's line-agnostic approval.
Lunsumio steps into Columvi territory
Sunmo succeeds in a setting very similar to Starglo's.
Exelixis claims a next-generation colorectal win
Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.
